Moderna. has been granted a patent for methods to treat solid tumors and lymphomas using LNP-encapsulated mRNAs that encode human OX40L, IL-23, and IL-36?. The method includes intratumoral injection of these mRNAs, potentially targeting conditions like triple negative breast cancer and melanoma. GlobalData’s report on Moderna gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Moderna, mRNA delivery lipid nanoparticles was a key innovation area identified from patents. Moderna's grant share as of June 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Lnp encapsulated mrna treatment for solid tumors and lymphomas
The granted patent US12042527B2 outlines a method for treating various cancers, including triple negative breast cancer, head and neck squamous cell carcinoma, melanoma, and Non-Hodgkin lymphoma, through the administration of a lipid nanoparticle (LNP) encapsulated mRNA composition. This composition consists of three specific mRNAs: one encoding a human OX40L polypeptide, another for a human IL-23 polypeptide, and a third for a human IL-36? polypeptide. Each mRNA is modified with uridines and is administered via intratumoral injection at doses ranging from 0.25 mg to 8 mg. The treatment regimen can vary, with administration occurring every 7 to 28 days, and the method aims to reduce tumor size or inhibit growth in both injected and uninjected tumors.
Additionally, the patent describes the potential for combining the LNP encapsulated mRNA composition with checkpoint inhibitor polypeptides, such as PD-1 or PD-L1 antagonists, including durvalumab, and CTLA-4 antagonists, such as tremelimumab. The mRNAs may also include specific microRNA binding sites to enhance their efficacy. The claims detail various dosing options, including specific doses for both the mRNA composition and the checkpoint inhibitors, with administration schedules set for every two or four weeks. This innovative approach aims to improve treatment outcomes for patients suffering from these aggressive forms of cancer.
To know more about GlobalData’s detailed insights on Moderna, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
